Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. CONCLUSIONS: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tirzepatide also leads to greater weight loss than semaglutide for people with type 2 diabetes 14 and than liraglutide for people with obesity.15”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“In the STEP-8 trial, 70 semaglutide 2•4 mg/week led to greater weight loss (a 15•8% reduction) compared with liraglutide 3•0 mg once daily (a 6•4% reduction); in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7%”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7% )”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“Similar differences in effectiveness are found when looking at reductions in waist circumference, systolic blood pressure, and serum triglycerides, with differences in effect sizes reflecting the differences in weight loss in response to liraglutide, semaglutide, and tirzepatide treatment.15,70”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“The efficacy of GLP-1 receptor agonists (GLP-1 RAs) in older adults has been robustly demonstrated in randomized controlled trials (RCTs) [34], providing strong evidence for their use in managing obesity and related comorbidities in individuals aged over 65.”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [34]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Whelton, P. K. (2002) · JAMA · doi:10.1001/jama.288.15.1882 · Cited by 1,473
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Self-citationTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Cited by
Items 301–400 of 590
Galindo, R. J., Aronne, L. J., Horn, D. B., Miras, A. D., Dunn, J. P., Cao, D., Lee, C. J., Karanikas, C. A., Heine, R. J., Falcón, B. L., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02895-3 · Cited by 3
Self-citationOn the Noninferiority of Tirzepatide
Kaul, S. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.085 · Cited by 1
Wartko, P. D., Zhang, R., Johnson, E., Begle, C., Bobb, J. F., Chen, C., Singh, A., ROSS, L. C., O’Connor, P. J., Arterburn, D. E., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113504
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis
Jian, L., Zhang, K., He, W., Ke, Y., Lü, Y., & Zhu, X. (2026) · View · doi:10.1002/viw2.70204
McCormick, N. P., de Moura, C. S., Zhang, J., Holladay, E. E., Xie, F., Mehta, T. S., Baker, J. F., & Curtis, J. R. (2026) · ACR Open Rheumatology · doi:10.1002/acr2.90068
Afentou, N., Hall, J., Ogwulu, C. O., Albon, E., Dretzke, J., Price, M., Clare, K., Singhal, R., Tahrani, A. A., Moore, D. J., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08854-4
Myśliwczyk, D., Myśliwiec, M., Minarowska, A., & Wasilewska, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188191
Balakrishnan, Y. S. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20262886
Alourfi, N. M., & Alorfi, N. M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s575375
Orale Einnahme von 25 mg Semaglutid bei Erwachsenen mit Übergewicht oder Adipositas
Finze, A., Otto, M., & Reißfelder, C. (2026) · Die Chirurgie · doi:10.1007/s00104-026-02452-x
Kim, Y., Kim, K. H., Lee, S. H., Moon, Y., Oh, Y., & Seo, K. W. (2026) · Journal of Metabolic and Bariatric Surgery · doi:10.17476/jmbs.2026.15.1.10
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
Pulsatile liraglutide on a biased tirzepatide background: a hypothesis
Kopitović, I. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922908
Long, Y., Xu, Z., Zhang, N., Chen, G., Chen, W., Chen, Z., Wang, A., Liang, Z., Wang, Y., Zeng, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.21.719783
LUBI, E. P., & Lubi, N. P. (2026) · RCMOS - Revista Científica Multidisciplinar O Saber · doi:10.51473/rcmos.v1i1.2026.2676
Obesity Pharmacotherapy: A Practical Approach to Patient-Centered Medication Selection
Park, J. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.4.194 · Cited by 1
Liu, H., 张庆红, Du, M., Hao, J., 牛玉梅, You, H., Cao, D., Tang, R., 杨艳艳, Wei, X., et al. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106740
Mehetre, K. N., & Dawane, J. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933913
Japanese nationwide surveys on bariatric/metabolic procedures in 2021–2024
Ohta, M., Seto, Y., Endo, Y., Naitoh, T., Hatao, F., Shiraishi, T., Yamamoto, H., Kasama, K., & Sasaki, A. (2025) · Surgery Today · doi:10.1007/s00595-025-03195-8
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01446-x
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
Rodriguez, P. J., Lusk, J. B., Mehta, H. B., Levy, J. F., Kalogeropoulos, A. P., Soneji, S., Do, D., Holler, E., Webber, E., Gluckman, T., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-109259 · Cited by 2
Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes
Liao, K., Kuo, C.-Y., Wu, J., Hsu, W., Tsai, Y., & Lai, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1928877
Emerging Therapeutic Agents for Obesity and Future Perspectives
Otoda, T. (2025) · Journal of Nihon University Medical Association · doi:10.4264/numa.84.4_185
Kotlyarov, S. N., & Котлярова, А. А. (2026) · Pharmacoepidemiology · doi:10.3390/pharma5030025
O’Brien, H., Byrne, A. J., Franciosi, A. N., & Butler, M. W. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00380-z
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
Whyte, M. (2025) · The Conversation · doi:10.64628/ab.eftghtjne
Contemporary medical therapy for heart failure with mildly reduced or preserved ejection fraction
Beavers, C. J., & Greene, S. J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10656-w
Humility, Uncertainty, and Shared Decisions: Lessons From Amyloidosis
Kittleson, M. M. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.10.013
Lifespan approaches for the prevention and management of steatotic liver disease
Zelber‐Sagi, S., Ivancovsky-Wajcman, D., Kugelmas, C., Weinstein, A. A., Wong, V. W., Castéra, L., Moore, J. B., Mouzaki, M., Hallsworth, K., Paik, J. M., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01198-5 · Cited by 2
What is “triple strength” Wegovy, and why has the MHRA approved it?
Lang, K. (2026) · BMJ · doi:10.1136/bmj.s111
Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review
Garcia, C. C., Moryousef, J., Pinthus, J. H., & Leong, D. P. (2026) · Cancers · doi:10.3390/cancers18152465
Adipositas und Diabetes mellitus Typ 2 (Update 2026)
Brix, J. M., Clodi, M., Harreiter, J., Hoppichler, F., Fw, K., Itariu, B.-K., Parzer, V., Resl, M., Schindler, K., Toplak, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02706-y
The role of bariatric metabolic endoscopy in 2026 and beyond
Norton, B. C., Ranganath, S., Bhandari, M., & Haidry, R. J. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103561
Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered Questions
Heerspink, H. J. L., Bjornstad, P., Cherney, D. Z. I., & van Raalte, D. H. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000838
Deng, C.-X., Chen, Z.-M., Tang, Y.-X., Xi, Z.-X., Wang, S.-Y., Wu, H.-Y., Xu, B., & Xu, T.-C. (2026) · World Journal of Pharmacology · doi:10.5497/wjp.v15.i1.113080
Салухов, В. В., Galstyan, G. R., Неймарк, А. Е., Samoilov, V. S., Khalimov, Y. S., Karonova, T. L., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-155
Medikamentöse Therapie der Adipositas
Malzner, A. (2026) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-026-00250-0
Patel, D., Ewida, H. A., Tareq, S., Aziz, M. T., Chelikani, P. K., Bickel, U., & Ahmed, M. S. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00404
Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Lejman, A., Mazurkiewicz, A., Sidor, H., Wołosik, M., & Zysiak, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4671
Crelier, V. T. C., Vidal, A. S., Braga, N., Figueiredo, M. R., de Almeida, S. A., Jorge, J. K. C., & de Freitas, G. R. (2026) · Cureus · doi:10.7759/cureus.110101
Clement, M. A., & Samuel, J. P. (2026) · Pediatric Nephrology · doi:10.1007/s00467-026-07293-8
Obstructive sleep apnea pharmacology
Sunwoo, B. Y., Schmickl, C. N., & Malhotra, A. (2026) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2026.2695024
Unpacking adiposity: a narrative critical appraisal of diverse obesity definitions
Mancini, M. C., Halpern, B., de Melo, M. E., & Kramer, C. K. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02261-6
Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly
Bianchettin, R. G., Poirier, P., López-Jiménez, F. A., Lavie, C. J., & Piché, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00777-2 · Cited by 1
Wu, K. A., Choudhury, A., Wu, J. A., Shenoy, D. A., Song, J., Mai, E., Dhanjani, S. A., Shatkin, M. S., Wellman, S. S., Seyler, T. M., et al. (2026) · The Knee · doi:10.1016/j.knee.2026.104639
Metabolic dysfunction and the use of adjunct medications in type 1 diabetes
Luk, A., Cheah, Y. S., Misra, S., & Salem, V. (2026) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000956
Santulli, G. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00321-4
Alevizopoulos, A. G., Vasilakos, V., Kritikos, I., Alevizopoulou, M., Korompoki, E., Ψαλτοπούλου, Θ., & Paschou, S. Α. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261457548
Modern pharmacological therapies in nephrology: Progress, promises, and the forgotten role of diet
Borges, N. A., Cardozo, L., Leal, V. D. O., da Silva, L. D. S. F. V., Wesson, D. E., Fouque, D. P., & Mafra, D. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106781
Beyond Weight Loss: Redefining MASLD Management Through Obesity Pharmacotherapy
Ravaioli, F. (2026) · European Medical Journal · doi:10.33590/emj/1463768r
Iglesias, P. C. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02828-0
Rajan, K., Jutley, A., Holliday, M. W., & Navaneethan, S. D. (2026) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s522424
Multisystem Benefits of GLP-1 Microdosing: A Narrative Review
Panlilio, M. A., Piserchio, N., Hennessey, M., Torres, K., Khan, S., & Choy, L. (2026) · Cureus · doi:10.7759/cureus.113635
Díaz, L. A. H., Alanis, B. A. L., Zorrilla-Núñez, L. F., & Muñoz-Maldonado, G. E. (2026) · Cureus · doi:10.7759/cureus.113460
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
Weight loss therapies and osteoporosis risk – Authors' reply
Ebeling, P., Ye, C., & Kline, G. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00105-4
Disparities in Medication Treatment of Type 2 Diabetes and Obesity
Whooten, R., Allen, L., & Stanford, F. C. (2026) · PEDIATRICS · doi:10.1542/peds.2025-074840
Prevention of cardiovascular disease
Hassan, N., & Iqbal, R. (2025) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380251364739
Monnier, L., Schlienger, J.-L., & Colette, C. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.002
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
The application of GLP-1 receptor agonists in obesity due to MC4R deficiency
Ding, M., Luo, Y., & Ji, L. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.58
Orozco, R., Romero, P., & Palacios, S. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02166-4
Clinical Application and Research Progress of Novel Anti-Obesity Medications
商, 博. (2026) · Pharmacy Information · doi:10.12677/pi.2026.154043
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Alhazmi, A., & le Roux, C. W. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2731087
Antza, C., Belančić, A., Jordan, J., Esteban, A., Oliveras, A., McNally, R., Anyfanti, P., Versmissen, J., Fernández‐Alfonso, M. S., Kotsis, V., et al. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70798
Li, J., Li, J., Xu, X., Wang, N., Lu, Y., & Wang, B. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03304-y
Sinaga, N., & Sirait, L. (2026) · Health & Medical Sciences · doi:10.47134/phms.v3i3.631
Carreiro, S. M., Ramos-Leví, A., Matía‐Martín, P., Madrid, B. B., Carrillo, C. R., Marcuello, C., Pérez‐Ferre, N., Torres-García, A. J., Sánchez-Pernaute, A., López-Jamar, J. M. E., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08954-1
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
Technology and Obesity: A Year in Review
Patra, S., Bhandarkar, A. P., Kapoor, N., & Kalra, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03775-1
Perspectives of Obstetricians and Gynaecologists on the Use of Weight Loss Medications
Nolan, C. E., Petch, S., Joyce, N., Glover, L. E., & Crosby, D. A. (2025) · Reproductive Female and Child Health · doi:10.1002/rfc2.70034
Kapan, A., Haider, S., Moser, O., Waldhoer, T., & Felsinger, R. (2025) · Obesity Facts · doi:10.1159/000550051
Campbell, C. A., Rubin, J. P., WELTMAN, A. L., Allen, J. D., & Angadi, S. S. (2026) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000008073
Bartkowiak, D., Jakubczyk, B., Lasota, A., Kopoczyński, Ł., Wiesner, M., Wodzinski, L., Boguszewski, K., Porazinski, H., Mlynarska, A., & Ratajski, O. (2026) · Cureus · doi:10.7759/cureus.116245
Heise, T., Zijlstra, E., Mari, A., Roell, W. C., Mather, K. J., Haupt, A., Flevaris, P., Liao, R., Chua, L., Harris, C., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70863
Azzam, A. Y., Essibayi, M. A., Rai, P., Salim, H. A., Alhasan, M. S., Anindo, M., Hashem, A. M., Dmytriw, A. A., Altschul, D., Yedavalli, V. S., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102917 · Cited by 1
Kitamoto, T., Yoshino, M., Shingaki, T., Oura, T., Valderas, E. G., & Dunn, J. P. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2695047
Self-citationMarqués-Vidas, M., Quiroga, B., Portolés, J. M., Ortíz, A., Fernández‐Fernández, B., Horrillo, A. S., Soler, M. J., García-Carro, C., Morales, E., & Bajo, M. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187201
Cacciapuoti, F. (2026) · Medical Sciences · doi:10.3390/medsci14010127 · Cited by 5
Farmakovijilansın Önemi: GLP-1 Reseptör Agonistlerinin Etkinlik ve Güvenliliği
Kayan, G. T., & Karataş, Y. (2026) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.1976223
Ganjre, S., Borah, L., & Khardenavis, A. (2026) · Cureus · doi:10.7759/cureus.117270
Prigozin, A., Cohen, M. J., Isaacson, A., Ronen, M., Sheinin, D. A., & Lahad, A. (2026) · Public Health · doi:10.1016/j.puhe.2026.106179
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2766-3375
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
GLP-1 Receptor Agonist Use in Cancer Survivors—Challenges and Opportunities: A Narrative Review
Agurs‐Collins, T., & Sauter, E. R. (2026) · Cancers · doi:10.3390/cancers18162714
de Assis, D. C. M., Coelho, F. M. M., de Melo, P. M., & dos Santos, D. W. (2026) · Research Society and Development · doi:10.33448/rsd-v15i7.51433
Li, Y., Ye, D., Fu, C., Huang, X., Ma, Q., Zhang, F., Chen, G., Song, P., Kong, C., Wu, J., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2687937
Brucar, L. R., Miller, K. M., & Volkow, N. D. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106990
New-Onset Heart Failure in Patients with Obesity using Tirzepatide or SemaglutidePreprint
Al-Nusair, M., Haddad, T. A., Khurana, S., & Al‐Nusair, J. (2026) · medRxiv · doi:10.64898/2026.09.21.26363546
Metadata
- Authors
- Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P.
- Affiliations
- Weill Cornell Medicine (US)
- University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston
- Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin
- University of California, Los Angeles (US)
- Eli Lilly, Indianapolis
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-07-03
- Volume
- 393
- Issue
- 1
- Pages
- 26-36
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410277932
- Cited by
- 634
- References
- 40
- Citations by year
- 2026: 448 · 2025: 186
- FWCI
- 355.83
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eCommons (Cornell University) (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company (NA)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- tirzepatide, semaglutide, obesity, weight loss, waist circumference, GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, gastrointestinal adverse effects, non-diabetic obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adult, Aged, Body Weight, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents, Maximum Tolerated Dose, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.